Recent advances in isatin hybrids as potential anticancer agents

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• The isatin framework is a validated scaffold for developing anticancer agents.
• Several isatin-based drugs (e.g., sunitinib) are approved or in clinical trials for various cancers.
• Isatin hybrids offer a strategy to enhance efficacy and manage drug resistance in cancer treatment.

Purpose of the Study:

• To review recent advancements in isatin-based hybrids with anticancer activity.
• To discuss structure-activity relationships (SAR) of these compounds.
• To guide the design of novel isatin hybrids with improved efficacy and reduced toxicity.

Main Methods:

• Comprehensive literature review of isatin-based hybrids published between 2001 and 2019.
• Analysis of reported anticancer activities and SAR data.
• Synthesis of findings to identify trends and future directions.

Main Results:

• Identified numerous isatin-based hybrids demonstrating significant anticancer potential.
• Detailed SAR studies reveal key structural features contributing to cytotoxic activity.
• Highlighted the potential of isatin hybrids to overcome multidrug resistance mechanisms.

Conclusions:

• Isatin-based hybrids represent a promising class of compounds for next-generation cancer therapeutics.
• Further research into SAR can optimize isatin hybrid design for enhanced potency and safety.
• This review provides a foundation for developing highly effective and low-toxicity anticancer agents.